CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

The CAR T Vision Steering Committee has set an ambitious goal: to double the proportion of eligible patients treated with CAR T by 2030. 2 Reimbursement challenges stand out as an area where ...

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. Doctors harvest the patient’s T cells, the soldiers of the immune ...

"The FDA approval of liso-cel in relapsed or refractory marginal zone lymphoma is a significant advancement in redefining the treatment landscape and providing patients with an option that has ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Today, a new approach is giving patients and their physicians reason to hope. Moffitt Cancer Center has expanded its ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

Outpatient CAR T therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole. Dr. Olalekan O. Oluwole, an attending ...

As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...